Evaluate REC-4881 in Patients With FAP

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Familial Adenomatous Polyposis
Interventions
DRUG

REC-4881

REC-4881 4mg capsules

DRUG

Placebo

Placebo capsules

Trial Locations (17)

19104

RECRUITING

University of Pennsylvania, Philadelphia

32825

ACTIVE_NOT_RECRUITING

Digestive and Liver Center of Florida, Orlando

34102

WITHDRAWN

GI Pros, Naples

37232

RECRUITING

Vanderbilt Digestive Center, Nashville

38108

ACTIVE_NOT_RECRUITING

Gastro One-8110 Walnut Rs, Cordova

47150

WITHDRAWN

Gastroenterology Health Partners, PLLC, New Albany

49503

RECRUITING

Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis), Grand Rapids

55905

RECRUITING

Mayo Clinic - Rochester, Rochester

63110

RECRUITING

Washington University School of Medicine, St Louis

70072

TERMINATED

Tandem Clinical Research, Marrero

75390

RECRUITING

Genetic Cancer Prevention Clinic - UT Southwestern, Dallas

77030

RECRUITING

MD Anderson Cancer Center, Houston

84112

RECRUITING

Huntsman Cancer Institute and University of Utah, Salt Lake City

85259

ACTIVE_NOT_RECRUITING

Mayo Clinic - Scottsdale, Scottsdale

85715

WITHDRAWN

Del Sol Research Management, Tucson

92123

WITHDRAWN

Medical Associates Research Group, San Diego

98101

RECRUITING

Benaroya Research Institute at Virginia Mason, Seattle

All Listed Sponsors
lead

Recursion Pharmaceuticals Inc.

INDUSTRY